Irinotecan dosing:: Does the CPT in CPT-11 stand for "Can't predict toxicity"?

被引：55

作者：

Ratain, MJ ^{[1
]}

机构：

[1] Univ Chicago, Canc Res Ctr, Comm Clin Pharmacol, Chicago, IL 60637 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2002年 / 20卷 / 01期

关键词：

D O I：

10.1200/JCO.2002.20.1.7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：7 / 8

页数：2

共 25 条

[1] UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan [J].

Ando, Y ;

Saka, H ;

Asai, G ;

Sugiura, S ;

Shimokata, K ;

Kamataki, T .

ANNALS OF ONCOLOGY, 1998, 9 (08) :845-847

[2] Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: The European perspective [J].

Bleiberg, H ;

Cvitkovic, E .

EUROPEAN JOURNAL OF CANCER, 1996, 32A :S18-S23

[3]

Chu XY, 1998, CANCER RES, V58, P5137

[4] Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver [J].

Farabos, C ;

Haaz, MC ;

Gires, P ;

Robert, J .

JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (06) :722-731

[5] CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues [J].

Guichard, S ;

Terret, C ;

Hennebelle, I ;

Lochon, I ;

Chevreau, P ;

Frétigny, E ;

Selves, J ;

Chatelut, E ;

Bugat, R ;

Canal, P .

BRITISH JOURNAL OF CANCER, 1999, 80 (3-4) :364-370

[6]

Gupta E, 1998, CLINICIAN'S GUIDE TO CHEMOTHERAPY PHARMACOKINETICS AND PHARMACODYNAMICS, P435

[7]

GUPTA E, 1994, CANCER RES, V54, P3723

[8]

Humerickhouse R, 2000, CANCER RES, V60, P1189

[9]

Innocenti F, 2001, DRUG METAB DISPOS, V29, P596

[10]

IYER I, IN PRESS PHARMACOGEN

← 1 2 3 →